MedTrace Logo

Efficacy and Safety of Immunotherapy in Non-small Cell Lung Cancer With Uncommon Histological Type

NCT05023837 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2022-01-25

No results posted yet for this study

Summary

This study was designed to explore the efficacy and safety of immune checkpoint inhibitor for advanced uncommon pathological types of lung cancer whether or not it is accompanied by a driver mutationin the real world. Through retrospective collection of clinical data of patients with uncommon pathological types of lung cancer.The patients who are treated with immunosuppressive agents are screened out, and they are divided into immune combination therapy or immune monotherapy, and further evaluate whether there is a difference in efficacy between the two.

Conditions

  • Uncommon Pathological Types of Lung Cancer

Interventions

DRUG

Pembrolizumab 100 MG Injection

Pembrolizumab iv 200mg q21d

Sponsors & Collaborators

  • Hunan Province Tumor Hospital

    lead OTHER

Principal Investigators

  • Yongchang Zhang, MD · Hunan Cancer Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-03-02
Primary Completion
2021-08-02
Completion
2021-08-03

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05023837 on ClinicalTrials.gov